T&R Biofab Obtains Patent for 3D Bioprinting Artificial Blood Vessel Manufacturing Technology

[Asia Economy Reporter Jang Hyowon] T&R Biofab, a 3D bioprinting specialized company (CEO Yoon Wonsu), has obtained a domestic patent for the '3D printing system for manufacturing artificial blood vessels and the method for manufacturing artificial blood vessels using the same.'

This patented technology is a method for manufacturing implantable artificial blood vessels using 3D bioprinting. It is a novel 3D bioprinting technique differentiated from existing methods by combining polymer printing technology for external shape fixation and cell printing technology for microvascular tissue.

In particular, the technology prints the company's self-developed bioink together with living cells to produce tubular artificial tissues similar to actual biological tissues. It can precisely replicate not only the structural shape but also the biological functions. This technology is expected to have increased applicability in the future, as it can be applied not only to artificial blood vessels but also to the production of artificial airways and artificial esophagi.

Yoon Wonsu, CEO of T&R Biofab, stated, "Once commercialized, this technology will receive significant attention not only in the domestic market but also overseas, providing an innovative alternative in the treatment of vascular diseases such as myocardial infarction and stroke. We will focus on advancing the technology and accelerating the timeline for commercialization and business development through dedicated research and development."

This content was produced with the assistance of AI translation services.